Press Releases
Media Contact:
Lorie Calvo
425-608-3008
Northwest Biotherapeutics, Inc.
(or "the Company”)
Holding(s) in Company
The Company was notified on 18 October 2007 that, Helium Special Situations Fund
has an interest in 2,302,632 Common shares representing approximately 5.48% of
the issued share capital of the Company.
19 October 2007
For further information, please contact:
Northwest Biotherapeutics
Alton Boynton, President and Chief Executive Officer |
+ 1 240 497 9021 |
Collins Stewart
Tim Mickley
Adam Cowen |
+44 (0)20 7523 8350
+44 (0)20 7523 8320 |
|
